Certara logo — The leading drug development consultancy with solutions span...

Certara

The leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development

Founded 2008 United States Princeton, United States 1514 employees Post IPO Total: $2.11B Biotechnology, Health Care +1

General Information

Company Name Certara
Founded Year 2008
Location United States Princeton, United States
Founders / Decision Makers
Team member
Employees 1514
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post IPO
Business Model B2B, SaaS, DaaS
Revenue Model Subscription, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Certara. To contact Certara, visit certara.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Certara compare?

A PDF of Certara and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Certara soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Certara

Certara, founded in 2008, is positioned as a leading consultancy in drug development, with a focus on biotechnology, healthcare, and pharmaceuticals. Headquartered in the United States, the company prides itself on its slogan: "The leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development."

The company excels by leveraging its proprietary biosimulation software and technology to streamline and enhance the drug discovery and development process. Serving a diverse clientele consisting of 2,000 biopharmaceutical firms, academic institutions, and regulatory agencies across 62 countries, Certara has established a robust presence in the global market.

Its most recent investment—a grant on 01 August 2023—from the US Food and Drug Administration solidifies its status as a valued partner in the regulatory space, further validating its strategic importance in the industry.

Business keywords: Biosimulation Software, Drug Discovery, Preclinical Development, Clinical Development, Pharmacokinetics (PK) Modeling, Pharmacodynamics (PD) Modeling, PBPK Modeling, Trial Design, Regulatory Science, Quantitative Systems Pharmacology, Model-Based Meta-Analysis, Clinical Pharmacology, Regulatory Strategy, Health Economics and Outcomes Research, Real World Evidence Solutions

Services & Products

predictive modeling and simulation
biometrics and data science
drug development support
regulatory strategy
market access strategies
biosimulation training
software integration

Target Customers

biotech companies large pharmaceutical companies contract research organizations (CROs) regulatory agencies scientists in drug development

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
US Food and Drug Administration
01 Aug 2023
Secondary Market $449.00M 1
Arsenal Capital Partners
01 Nov 2022
Grant $139.50M -
01 Sep 2021
IPO $668.00M -
01 Dec 2020
Buyout $850.00M 1
EQT Group
01 Jul 2017

Certara Alternatives & Competitors

View All Alternatives
Certara vs

The experts in AI technology for drug discovery and development.

Series C
182 employees
AI, Analytics
Certara vs

Cognigen Services is now a part of Simulations Plus, providing clinical pharmacology and pharmacomet...

34 employees
Biotechnology, Health Care
Certara vs

Nova has built jinkō, a unique in silico clinical trial simulation platform to de-risk and accelerat...

Series A
61 employees
Biotechnology, Health Care

FAQ About Certara

The leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development
Certara was founded in 2008.
Certara is headquartered in Princeton, United States.
Certara operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biosimulation Software, Drug Discovery, Preclinical Development and Clinical Development. Its customers include biotech companies, large pharmaceutical companies and contract research organizations (CROs).
Certara has a B2B, SaaS and DaaS business model. Its revenue comes from Subscription, Service Fee and Licensing.
Certara has approximately 1514 employees.
Certara has completed 5 funding rounds, raising a total of $2.11B. The latest funding stage is Post IPO.
Certara offers: predictive modeling and simulation, biometrics and data science, drug development support, regulatory strategy, market access strategies, biosimulation training, software integration.
Top alternatives and competitors to Certara include Partex.AI Technology, Cognigen Corporation, a division of Simulations Plus, Nova In Silico, BioPoint Inc., Reaction Biology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Certara and Partex.AI Technology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Certara, https://bouncewatch.com/company/certara, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes